References
Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32(6):504–12.
Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406.
Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24.
Turner K, Delman M, Vaysburg D, et al. Systemic therapy for resected pancreatic adenocarcinoma: how much is enough? Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-022-11363-0
Funding
The authors have no grants or financial support to report.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Kevin M. Turner and Sameer H. Patel have no disclosures to report.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Turner, K.M., Patel, S.H. ASO Author Reflections: An Underappreciated Metric: Systemic Chemotherapy Dose Density in Pancreatic Cancer. Ann Surg Oncol 29, 3473–3474 (2022). https://doi.org/10.1245/s10434-022-11390-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-022-11390-x